Propanc Biopharma (OTCMKTS:PPCB) Stock Price Up 6.5% – Should You Buy?

Propanc Biopharma Inc (OTCMKTS:PPCB)’s stock price was up 6.5% during trading on Friday . The stock traded as high as $0.5957 and last traded at $0.5717. Approximately 64,458 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 631,006 shares. The stock had previously closed at $0.5366.

Propanc Biopharma Trading Up 6.5%

The company has a market capitalization of $7.32 million, a PE ratio of -0.01 and a beta of 3.30. The company has a fifty day simple moving average of $0.85 and a 200-day simple moving average of $2.82. The company has a current ratio of 2.24, a quick ratio of 2.24 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Propanc Biopharma

A hedge fund recently bought a new position in Propanc Biopharma stock. Virtu Financial LLC purchased a new position in shares of Propanc Biopharma Inc (OTCMKTS:PPCB) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned 0.33% of Propanc Biopharma at the end of the most recent quarter.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.